Abstract 18P
Background
Compared to sequential conventional fractionation schedule, Simultaneous integrated Boost provides increased dose homogeneity, with less unintended excessive dose outside the boost area; in combination with a higher dose per fraction to the tumour bed, resulting in a shorter overall treatment time spanning over 5 1⁄2 weeks. We compared cosmesis using the Harvard cosmesis scale and dosimetry of SIB IMRT versus sequential electron boost in breast cancer patients.
Methods
Patients in our Institute who have undergone breast-conserving surgery and received adjuvant chemotherapy, who are referred for adjuvant radiotherapy. The study period spanned from 1st May 2016 to 31st March 2018.
Results
The baseline Harvard score for grading breast cosmesis in both the arms was excellent (84% in SIB and 81% in SEB) or good(16% in SIB and 19% in SEB). None of the patients in either arm had fair or poor cosmesis. Assessment of cosmesis at the end of radiation therapy showed a dip from excellent to good and fair in both the arms ( 34% versus 9% with excellent cosmesis, 53% versus 72% with good cosmesis and 13% versus 19% with poor cosmesis in SIB versus SEB arms) but the patients in the SEB arm had comparatively much lower cosmetic score. However, this difference was not statistically significant(p=0.045). Overall cosmesis at the end of 3 months was better in SIB arm compared to that of the SEB arm and was statistically significant (93% with excellent and good cosmesis in SIB vs 65% in SEB p<0.001). At 6 months of follow-up in SIB arm, there was an improvement of the cosmesis with a majority of the patients showing excellent(59%) and good (34%) cosmetic score.
Conclusions
In a selected cohort of patients who have undergone breast conservation surgery, a simultaneous integrated boost along with WBI is considered equivalent radiobiological to sequential electron boost after WBI. This study reports better cosmetic outcomes and favourable toxicity profile with SIB compared to SEB over short-term follow-up which is statistically significant.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session